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Background. Heart transplantation (HT) is a life-saving treatment for patients with end-stage heart failure. One of the 
main problems after HT is the humoral response termed antibody-mediated rejection (AMR). Complement activation 
plays a key role in AMR contributing to graft damage. The aim of this study was to analyze genetic variants in genes 
related to the complement pathways that could be associated with the development of AMR. 
Methods. Analysis of 51 genes related to the complement pathway was performed by next-generation sequencing in 
46 HT recipients, 23 with and 23 without AMR. Statistical analysis was performed with SNPstats and R. 
Results. We identified 2 single nucleotide polymorphisms, 1 in the mannose-binding lectin 2 gene (p.Gly54Asp-
MBL2) and 1 in the complement factor properdin gene (p.Asn428(p=)-CFP), that showed significant association with 
the absence and development of AMR, respectively. Moreover, the presence of the rare allele in p.Gly54Asp-MBL2 
control patients correlated with an immunodeficiency of mannose-binding lectin (6.24 ng/ml vs 207.50 ng/ml, p < 
0.01), whereas the presence of the rare allele p.Asn428(p=)-CFP in patients with AMR correlated with higher levels 
of properdin protein (14.65 μg/ml vs 10.77 μg/ml, p < 0.05). 
Conclusions. AMR is a complex phenotype affected by many recipient factors. Variants in p.Gly54Asp-MBL2 and 
p.Asn428(p=)-CFP genes, encoding mannose-binding lectin 2 and properdin, may influence the risk of AMR. 
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Heart transplantation (HT) is a well-established life-saving treatment for patients presenting with end-
stage cardiac failure. However, it has been established that approximately 15%–25% of patients who 
receive a transplant experience cell-mediated rejection episodes, and some develop antibody-mediated 
rejection (AMR).
1,2
 AMR in HT is associated with hemodynamic compromise, increased graft loss, 
cardiac allograft vasculopathy (CAV), and increased mortality.
2
 The true incidence of AMR is unknown; 
however, values ranging from 3% to 85%, owing to diverse diagnostic criteria and variations in screening 
frequency, have been reported.
3,4
 Our research group reported an incidence of <3% when using the 
criteria of allograft dysfunction and C4d deposition in endomyocardial biopsy.
5
 
 
Allograft rejection caused by antibodies can be mediated by different mechanisms, as opposed to T-
cell rejection. Classically, antibody induces acute rejection through the fixation and activation of the 
complement cascade, resulting in tissue injury.
4,6
  Complement, which is a multicomponent system of 
receptors, regulators, and effector molecules, is a very powerful amplifier of the innate and adaptive 
immunity contributing to the pathogenesis of AMR.
6,7
  
 
More than 50 genes encoding proteins of complement components, receptors, and regulators have 
been described.
8
 The complement system consists of many proteins, mainly proteases, which create a 
cascade when triggered.
9
 There are 3 pathways of complement activation (Figure S1, available in the 
online version of this article at www.jhltonline.org): (1) the classical pathway, which is activated by 
antibodies bound to antigens and forming immune complexes; (2) the lectin pathway, which is activated 
by carbohydrates such as mannose-binding lectin (MBL); and (3) the alternative pathway, which is 
activated in the absence of antibodies by spontaneous hydrolysis of C3. Each pathway converges in the 
formation of a C3 convertase molecule, whose function is to cleave C3. 
 
Several polymorphisms and mutations in genes related to the complement system have been 
associated with different diseases, including renal, ocular, and infectious diseases.
8,10–12
 In the field of 
transplantation, most studies have focused on renal transplant outcomes. For example, the GGCG 
haplotype and 450 C/T polymorphism in C5 and C5a genes were associated with lower renal allograft 
function
13
 and low risk for graft rejection,
14
 respectively, whereas a polymorphism in CD46 was 
associated with acute renal allograft rejection.
15
 Moreover, mutations in complement genes may predict 
recurrence and graft outcome in renal transplant recipients with a typical hemolytic-uremic syndrome.
16,17
 
However, other studies showed no association between polymorphisms in C3 and lectin complement 
pathway genes and graft outcome.
18–20
 One limitation of these studies was that they analyzed <6 genes 
involved in the complement pathway.
13–20
 Recently, Ermini et al
21
 analyzed the relationship between 
single nucleotide polymorphisms (SNPs) in 47 complement genes and graft survival, serum creatinine, 
delayed graft function, and acute rejection in donors and recipients of renal transplants. They found 1 
donor SNP, c.304+363T>C (rs4935047), in the non-coding region of the mannose-binding lectin 2 gene 
(MBL2) associated with worse graft outcome. 
 
In HT, several genetic polymorphisms in cytokine genes have been associated with the risk of acute 
rejection.
22
 Despite the important role of complement in AMR, no study to our knowledge has described 
the role of variants in complement genes in AMR after HT. Thus, the aim of the present study was to 
investigate the association between variants in complement genes and the development of AMR after HT. 
  
Methods 
Patients 
A retrospective case-control study was conducted in samples from a historical cohort of patients who 
received a HT at Complejo Hospitalario Universitario de A Coruña (CHUAC) from June 2000 until 
November 2016. The study was carried out on 46 HT recipients, 23 with and 23 without AMR. The 23 
AMR cases were matched to 23 control patients by sex, age (±5 years), and follow-up post-transplant. 
 
The diagnostic criteria to define the cases of AMR were different according to whether the transplant 
date was before or after 2013. AMR in patients who underwent HT before 2013 (n = 15) was defined 
according to the following criteria: (1) allograft dysfunction (left ventricular ejection fraction < 30% 
and/or heart failure), (2) no evidence of other causes of allograft dysfunction (acute cellular rejection or 
CAV), (3) evidence of complement activation on endomyocardial biopsy (C4d and/or C3d staining), and 
(4) favorable response to therapy addressing AMR (e.g., plasmapheresis, rituximab, steroid boluses). 
AMR in patients who underwent HT after 2013 (n = 8) was classified according to International Society 
for Heart and Lung Transplantation (ISHLT) categories pAMR1(I+), pAMR1(H+), pAMR2, and 
pAMR3
23
 and inclusion criteria of having at least 1positive endomyocardial biopsy (pAMR1 or higher). 
Control patients did not present with any distinguishing signs of AMR (pAMR0) or allograft dysfunction. 
Each control patient was followed a minimum of 6months longer than the AMR event of the 
corresponding case. All HT recipients provided biological samples for DNA analysis. 
 
All samples used for this work had been stored in the collection of samples for research of the 
advanced heart failure and cardiac transplant unit of CHUAC (“Colección de muestras para la 
investigación de insuficiencia cardiac avanzada y trasplante cardiaco” registered in the Instituto de Salud 
Carlos III as C_0000419, 2012/348). The study was approved by the local Ethics Committee (“Comité 
ético de investigación de Galicia,” reference: 2014/012) and conformed to the ethical guidelines of the 
Declaration of Helsinki. Written informed consent was obtained for sample collection and genetic 
screening tests. 
Genetic study 
Genomic DNA was isolated from clots and blood samples using QIAamp DNA Blood Mini Kit 
(Qiagen GmbH, Hilden, Germany) following the manufacturer’s instructions and was stored at 4°C until 
use. The genetic analysis included 51 genes related to the complement pathway (Figure S1 and Table S1, 
available in the online version of this article at www.jhltonline.org). For this purpose, target resequencing 
was performed using TruSight One Sequencing Panel (Illumina, San Diego, CA), consisting of 4,813 
genes, including the 51 genes selected. The sequence library was constructed using 50 ng of each 
genomic DNA, quantified with Qubit 2.0 (Life Technologies). The NextSeq500 platform (Illumina) was 
used to perform 151-bp paired-end sequencing according to manufacturer’s instructions. The sequencing 
reads were aligned to the human reference genome (hg19). The extracted variants, reported invariant call 
format output file, were evaluated for coverage and Qscore. In addition, coding and adjacent intronic 
regions of the 51 genes were visualized via Integrative Genomics Viewer to confirm the presence of the 
variants detected. 
In silico tools 
The potential effect of missense SNP sassociated with AMR was predicted using in silico tools. 
Moreover, the minor allele frequency (MAF) of the SNPs detected by next-generation sequencing (NGS) 
was extracted from the Single Nucleotide Polymorphism Database (dbSNP) and/or the Exome 
Aggregation Consortium (ExAC). 
  
Localization 
Topologic placement of the mutations was done using the Swissprot database 
(http://ca.expasy.org/uniprot/) and the bibliography previously described. The Uniprot database provides 
generally accepted residue ranges corresponding with each domain region and specialized subregion. 
TheSwiss-Pdb Viewer (v.4.10) was used to generate the models of the mutated protein structure by 
replacing the native aminoacid for the variant. 
Predicting damagingaminoacidsubstitution 
Three online tools were used to predict the pathogenicity of the missense variants: SIFT 
(http://sift.jcvi.org/www/SIFT_seq_submit2.html), Polyphen-2 (http://genetics.bwh.harvard.edu/%20 
pph2/), and PhDSNP (http://snps.uib.es/phd-snp/phdsnp.html). The ClinVar database was also consulted. 
Sanger sequencing 
Direct sequencing of 15 amplicons (Table S2, available in the online version of this article at 
www.jhltonline.org), containing at least 1 variant by NGS each, was performed to evaluate sensitivity 
[TP/(TP+FN)], specificity [TN/(TN+FP)], and accuracy [(TP+TN)/(TP+FP+FN+TN)] of the NGS 
technique. In these formulas, TPmeans true-positive, TN means true-negative, FP means false-positive, 
and FN means false-negative. 
Enzyme-linked immunosorbentassay measurements 
Pre-transplant serum samples were used for the determination of functional MBL(n = 9, 5 samples 
from patients with AMR with the reference sequence in the position c.161 and 4 samples from control 
patients that carried the variant c.161G>A) and properdin (n = 16, 5 with AMR and variant c.1284C>T 
and 11 without AMR and with the reference sequence in the position c.1284) levels, using commercially 
available competitive sandwich enzyme-linked immunosorbent assay kits (MBL, Human, ELISA kit 
HK323-01, and Properdin, Human, ELISA kit HK334-01) from Hycult Biotech(Uden, Netherlands). 
 
MBL measurable concentration range was 0.4–100 ng/ml. Serum samples were diluted 1:10 with 
MBL-binding buffer, and all measurements were made in duplicate. Properdin measurable concentration 
range was 0.3–20 ng/ml. Serum samples were diluted 1:2,000 with dilution buffer, and all measurements 
were made in triplicate. In both cases, the absorbance at 450 nm was measured in a spectrophotometer. 
The concentration of MBL varies among individuals from <5 to >5,000 ng/ml
24
; the properdin 
concentration varies from 5 to 15 μg/ml.25 
Statistical analyses 
Continuous variables are expressed as mean ± SD. Discrete variables are shown as percentage. For the 
genetic analysis, multiple inheritance models (codominant, dominant, recessive, and log-additive) were 
first applied by using SNPStats software. In addition, the genetic analysis was redone using R software 
for SNPs with significant allele association with any of the multiple models. Differences in allele and 
genotype frequencies between the 2 groups were assessed by McNemar’s chi-square test using R. A p-
value of 0.05 was used as a significance threshold. 
 
For analysis of serum levels, values were expressed as median and interquartile range (IQR). To 
assess the significance of differences of protein serum levels, the Mann-Whitney U test for non-normally 
distributed values was performed using R software. p < 0.05 was considered statistically significant. The 
R package and commands used to perform the statistical analyses are presented in the supplementary data 
(available in the online version of this article at www.jhltonline.org). 
Results 
Baseline clinical characteristics 
Of the 46 patients studied, 86.96% were men, and the mean age of recipients at time of transplantation 
was 50.1 years ± 16.0 (Table 1). The mean follow-up post-transplant was 7.3 years ± 3.6, and the most 
common heart disease in patients requiring HT was ischemic cardiomyopathy (39.1%). Table 1 displays 
the study population demographics, including immunosuppressive regimens. Furthermore, available data 
from the characterization of anti-HLA antibodies in both patients with AMR and control patients were 
included (Table S3, available in the online version of this article at www.jhltonline.org). Using the 
pathologic AMR classification in patients after 2013,
23
 4 patients were classified as pAMR(I+), and 4 
patients were classified as pAMR2. 
Table 1. Clinical CharacteristicsofPatients 
Variable  
Total 
(n = 46 patients) 
AMR 
(n = 23 patients) 
Control 
(n = 23 patients) 
    
Age, years, mean ± SD  50.1 ± 16.0  50.2 ± 16.5  50.0 ± 15.9 
Male  87.0% (40)  87.0% (20)  87.0% (20) 
Female  13.0% (6)  13.0% (3)  13.0% (3) 
Primary heart disease    
Dilated cardiomyopathy  34.8% (16)  26.1% (6)  43.5% (10) 
Ischemic cardiomyopathy  39.1% (18)  52.2% (12)  26.1% (6) 
Valvular cardiomyopathy  10.9% (5)  8.7% (2)  13.0% (3) 
Others  15.2% (7)  13.0% (3)  17.4% (4) 
Time since transplant    
< 2 years  10.4% (5)  17.4% (4)  4.4% (1) 
2–5 years  23.9% (11)  30.4% (7)  17.4% (4) 
≥ 6 years  65.2% (30)  52.2% (12)  78.3% (18) 
Time to AMR diagnosis after transplant, years, mean ± SD  3.5±0.6  
Cytomegalovirus status    
Donor +/recipient +  58.7% (27)  56.5% (13)  60.9% (14) 
Donor −/recipient –  2.2% (1)  0  4.4% (1) 
Donor +/recipient –  23.9% (11)  30.4% (7)  17.4% (4) 
Donor −/recipient +  13.0% (6)  13.0% (3)  13.0% (3) 
Unknown  2.2% (1)  0  4.4% (1) 
Immunosuppression    
Cyclosporine  75.0% (36)  75.0% (18)  75.0% (18) 
Plasmapheresis  32.6% (15)  65.2% (15)  0 
Rituximab  32.6% (15)  65.2% (15)  0 
Steroids  100% (46)  100% (23)  100% (23) 
OKT3  6.5% (3)  12.5% (3)  0 
Mycophenolate mofetil  91.3% (42)  87.0% (20)  95.7% (22) 
Tacrolimus  56.5% (26)  65.2% (15)  47.4% (11) 
Everolimus  32.6% (15)  26.1% (6)  39.1% (9) 
Basiliximab  89.1% (41)  82.6% (19)  95.7% (22) 
Sandimmune  14.6% (7)  20.8% (5)  8.3% (2) 
Daclizumab  4.4% (2)  4.4% (1)  4.4% (1) 
    
 
AMR, antibody-mediated rejection. 
  
Genotype association with AMR 
After sequencing all coding regions and the ±10 intronic pair bases in 51 genes related to the 
complement pathway (Figure S1, available in the online version of this article at www.jhltonline.org), 
319 polymorphisms in 50 genes were found (Figure 1A and Table S4, available in the online version of 
this article at www.jhltonline.org). No SNPs were found in CD59 gene. The mean coverage overall the 
genes related to the complement cascade was 72.7-fold ± 2.4 (Figure 1B). To determine the accuracy, 
specificity, and sensitivity of the NGS protocol, we followed 42 selected amplicons containing at least 1 
variant by NGS. From 8,481 readable bases in the Sanger sequencing, we observed 8,445 TN calls and 33 
TP calls. No FP calls and 3 FN calls were found, together resulting in a sensitivity of 91.7%, specificity 
of 100%, and accuracy of 99.7%. After manual inspection of the FN calls that only had been identified by 
Sanger, we detected that all FN calls appeared in the IGHA1 gene in the position chr14:106.173.808. 
However, in the 3 samples, Integrative Genomics Viewer allowed visualization of the variant in < 10% 
readings. Thus, we postulated that these FN must be related to the quality of the sequence in this position. 
 
A genetic association study was carried out to test for an association between AMR and 
polymorphisms in the complement cascade genes. First, an analysis with SNPstats was performed. The 
results showed that, from the 319 SNPs found, 8 variants (rs1048118-CFP, rs1800450-MBL2, 
rs11627594-IGHG2, rs1407-IGHA1, rs1130656-PLG, rs1450656-C7, rs17611-C5, rs25681-C5) were 
associated with AMR in at least 1 of the multiple inheritance models applied. Second, when the 
association function of R was applied, all 8 SNPs previously identified were significantly associated with 
AMR. However, when the McNemar chi-square test was done, only 2 SNPs were significantly associated 
with AMR: (1) the missense variant c.161G>A, p.Gly54Asp in MBL2 gene, rs1800450 (Table 2), and (2) 
the synonymous variant c.1284C>T, p.Asn428(p=) in CFP gene, rs1048118 (Table 3). 
 
 
 
  
 
 
 
Figure 1. SNP distribution per gene and sequence coverage. (A) Bar graph showing the distribution of SNPs per gene. (B) Graph 
representing the sequence coverage of the genes related to the complement cascade analyzed in the study. Overall complement 
genes mean coverage is 72.7 ± 2.4. 
  
Table 2. Statistical Analysis of Variant p.Gly54Asp (rs1800450) in MBL2 Gene in Control and AMR Groups 
rs1800450  Model Genotype Control AMR OR (95%CI)  p-value  AIC BIC  
         
SNPstats  Codominant G/G 13 (56.5%) 21 (91.3%) 1.00 0.02a  61.7  67.2  
  G/A  9 (39.1%) 2 (8.7%) 0.1 (0.03–0.7)     
  A/A  1 (4.3%) 0 (0%) 0.00 (0.00–NA)     
 Dominant G/G 13 (56.5%) 21 (91.3%) 1.00 0.006a  60  63.7  
  G/A-A/A  10 (43.5%) 2 (8.7%) 0.12 (0.02–0.66)     
 Recessive  G/G-G/A 22 (95.7%) 23 (100%) 1.00 0.2 66.4 70  
  A/A  1 (4.3%) 0 (0%) 0.00 (0.00–NA)    
 Overdominant  G/G-A/A 14 (60.9%) 21 (91.3%) 1.00 0.01a  61.5  65.2  
  G/A  9 (39.1%) 2 (8.7%) 0.2 (0.03–0.8)    
 Log-additive  —  —  —  0.1 (0.03–0.7)  0.005a  59.7  63.4  
R (F(x)association) Codominant G/G 13 (56.5%) 21 (91.3%) 1.00 0.02a  61.7  
  G/A  9 (39.1%) 2 (8.7%) 0.1 (0.03–0.7)    
  A/A 1 (4.3%) 0 (0%) 0.00    
 Dominant  G/G 13 (56.5%) 21 (91.3%) 1.00 0.005a  60   
  G/A-A/A  10 (43.5%) 2 (8.7%) 0.1 (0.02–0.7)    
 Recessive  G/G-G/A 22 (95.7%) 23 (100%) 1.00 1 66.4   
  A/A  1 (4.3%) 0 (0%) 0.00    
 Overdominant  G/G-A/A 14 (60.9%) 21 (91.3%) 1.00 0.01a  61.5   
  G/A  9 (39.1%) 2 (8.7%) 0.2 (0.03–0.8)    
Log-additive  —  —  —  0.1 (0.03–0.7)  0.02a 59.7    
McNemar’s test Chi-square = 4.9 with1 df   0.03a    
        
 
AIC, Akaike information criterion; AMR, antibody-mediated rejection; BIC, Bayesian information criterion; CI, confidence 
interval; OR, odds ratio. aStatistical significance. 
Table 3. Statistical Analysis of Variant rs1048118 in CFP Gene in Control and AMR Groups 
rs1048118 Model  Genotype  Control AMR OR(95%CI) p-value  AIC BIC 
         
SNPstats  Codominant  C/C 21 (91.3%) 12 (52.2%) 1.00  0.007a  59.7  65.2 
  C/T  0 (0%) 2 (8.7%) NA (0.00–NA)    
  T/T  2 (8.7%) 9 (39.1%) 7.9 (1.5–42.6)    
 Dominant  C/C 21 (91.3%) 12 (52.2%) 1.00 0.002a  58.4  62.1 
  C/T-T/T  2 (8.7%) 11 (47.8%) 9.6 (1.8–50.9)    
 Recessive  C/C-C/T 21 (91.3%) 14 (60.9%) 1.00 0.01a  61.5  65.2 
  T/T  2 (8.7%) 9 (39.1%) 6.8 (1.3–36.0)    
 Overdominant  C/C-T/T 23 (100%) 21 (91.3%) 1.00 0.09 64.9 68.6 
  C/T  0 (0%) 2 (8.7%) NA (0.00–NA)    
 Log-additive — — — 3.1 (1.3–7.4)  0.004a  59.5  63.2 
R (F(x)association) Codominant C/C 21 (91.3%) 12 (52.2%) 1.00 0.009a  59.7  
  C/T  0 (0%) 2 (8.7%) 0.00    
  T/T  2 (8.7%) 9 (39.1%) 7.9 (1.5–42.6)    
 Dominant  C/C 21 (91.3%) 12 (52.2%) 1.00 0.002a  58.4  
  C/T-T/T  2 (8.7%) 11 (47.8%) 9.6 (1.8–50.9)    
 Recessive  C/C-C/T 21 (91.3%) 14 (60.9%) 1.00 0.01a  61.5  
  T/T  2 (8.7%) 9 (39.1%) 6.8 (1.3–36.0)    
 Overdominant  C/C-T/T 23 (100%) 21 (91.3%) 1.00  0.4889 64.9  
  C/T  0 (0%) 2 (8.7%) 0.00    
 Log-additive — — —  3.1 (1.3–7.4) 0.009a  59.5  
McNemar’s test Chi-square equals 5.8 with 1 df   0.02a   
       
 
AIC, Akaike information criterion; AMR, antibody-mediated rejection; BIC, Bayesian information criterion; CI, confidence 
interval; OR, odds ratio. 
a Statistical significance. 
  
The polymorphismin MBL2 gene is a guanine-to-adenine substitution on the c.161 nucleotide that 
produces the substitution of the 54 glycine for aspartic acid (p.Gly54Asp) (Figure 2A, B). The MAF 
(allele = A) described in dbSNP is 0.1389; however, in our patients the rare allele was significantly more 
frequent in the control patients than in the patients with AMR (Table 2). Although p.Gly54Asp is a 
polymorphism, 3 software predictions showed that this variant can present an impact in the function of 
the protein (Figure 2C). Moreover, in the ClinVar database, this allele is described as a pathogenic allele. 
The second SNP associated with AMR was presented in the CFP gene, which codes for properdin protein. 
It is a cytosine-to-thymine substitution on the c.1284 nucleotide that does not modify the 428 asparagine 
aminoacid (p. Asn428(p=)) (Figure 3A, B). The MAF (allele = T) described in dbSNP is 0.2287; 
however, in our patients the rare allele was significantly more frequent in patients who developed AMR 
than in control patients (Table 3). 
 
 
 
   
 
Figure 2. MBL2 transcript, MBL primary domains, and MBL 
protein structure. (A) Schematic structure of the human MBL2 
gene showing relative position of the common polymorphis 
mrs1800450 (c.161G4A). (B) Primary protein domains of 
MBL and the relative location of the common polymorphism 
rs1800450 (p.Gly54Asp). The N-terminal cysteine-rich 
domain (21–41) is shown in orange, the collagen-like domain 
(42–99) is shown in gray, the coiled coil structure (112–130) 
is shown in green, and the cytoplasmic tail (134–245) is 
shown in blue. Red spots (A,B) indicate the polymorphism 
position.(C) In silico predictions of the effect of p.Gly54Asp 
variant. (D) MBL serum levels according to MBL2 genotype 
among 4 control patients who carried the variant p.Gly54Asp 
and 5 patients with AMR in which the analyzed SNP was not 
present. 
  
Figure 3. CFP transcript and properdin primary domains. (A) 
Schematic structure of the human CFP gene showing relative 
position of the common polymorphism rs1048118 
(c.1284C4T). (B) Primary protein domains of properdin and 
the relative location of the common polymorphism rs1048118 
(p.Asn428(p=)). Seven thrombospondin type-1 (TSP1) 
domains are shown in blue. Red spots (A,B) indicate the 
polymorphism position. (C) Properdin serum levels according 
to CFP genotype among 5 patients with AMR who carried the 
variant and 11 control patients with out the studied variant. 
 
  
Serum MBL levels in control patients vs patients with AMR correlated with described genotype 
The median MBL serum level measured before HT in 4 patients who did not develop AMR and 
carried the variant p.Gly54Asp was 6.2 ng/ml (IQR5.1–6.9 ng/ml) (Figure 2D). This value was 
significantly lower compared with the median MBL serum level measured before transplantation in 5 
patients with AMR in whom the analyzed SNP was not present (207.5 ng/ml (IQR84.8–290.9 ng/ml), p < 
0.01). Thus, these findings confirm that control patients who carried the SNP rs1800450 present low 
MBL levels. 
Serum properdin levels in patients with AMR correlated with described genotype 
Median properdin serum levels of 5 patients with AMR who carried the variant rs1048118 was 14.7 
μg/ml (IQR 12.0–36.4 μg/ml), whereas median serum levels of 11 control patients without the studied 
variant was 10.8 μg/ml (IQR 5.9–13.9 μg/ml). Thus, the genotype rs1048118 in patients with AMR was 
positively and significantly associated with higher concentrations of properdin (p < 0.05)(Figure3C). 
Secondary association between p.Gly54Asp-MBL2 and p.Asn428(p=)-CFP and CAV 
Owing to the relationship between CAV and AMR,
3
 a secondary genetic association study was also 
carried out to test for an association between CAV and p.Gly54Asp-MBL2 and p.Asn428(p=)-CFP genes, 
which are associated with AMR. CAV in transplant recipients were classified according to ISHLT 
categories (CAV1, CAV2, and CAV3).
2
 Using the pathologic CAV classification,
26
 8 patients were 
classified as CAV1, 2 patients were classified as CAV2, and 2 patients were classified as CAV3. The 
correlation analysis, performed with SNPstats and R software, showed a nonsignificant association for 
SNP (MBL2 [p > 0.99] and CFP [p > 0.2]) and CAV. 
Discussion 
To our knowledge, the present study represents the largest and the most exhaustive study to date on 
the effect of variants on genes involved in the complement pathway related to AMR in HT recipients. We 
have identified 2 SNPs, p.Gly54Asp-MBL2, which is associated with absence of AMR, and 
p.Asn428(p=)-CFP, which is associated with the development of AMR. Moreover, the presence of the 
rare allele p.Gly54Asp-MBL2 in control patients correlates with an immunodeficiency of MBL, whereas 
the presence of the rare allele p.Asn428(p=)-CFP in patients with AMR correlates with higher levels of 
properdin protein. 
Protective role of p.Gly54Asp in MBL2 gene from AMR 
p.Gly54Asp is the first SNP significantly and negatively associated with AMR. The higher frequency 
of this variant in control patients correlates to lower concentration of MBL, which could be classified as 
MBL deficiency (<100 ng/ml). MBL2 gene codes for MBL protein, which is the initiator of the 
complement lectin pathway and a key component of the activation of the innate immune system.
27
 The 
polymorphism p.Gly54Asp presents an MAF between 0.1220 (dbSNP—1000 Genomes) and 0.1389 
(ExAC), and the in silico tools used in this study predict a deleterious effect. It has been previously 
described that the presence of this polymorphism in heterozygous individuals produces an MBL 
deficiency.
28
 This effect is confirmed with our data showing low concentration (median = 6.2 ng/ml) of 
MBL in our control patients who carry the variant. However, most of the previous studies associated the 
presence of p.Gly54Asp with decreased host defense against various infectious agents.
27
 In the field of 
transplantation, most studies related to p.Gly54Asp have focused on renal transplant outcomes. The 
results were inconclusive because some studies failed to find an association between genetic profile of the 
lectin pathway of complement activation and allograft outcome in renal transplants,
19,21
 whereas others 
showed a relationship with the incidence of acute rejection and graft outcome.
29,30 
 
In HT, 2 studies described MBL deficiency related to development of CAV
31
 and acute graft 
rejection.
32
 However, neither study analyzed the presence or absence of the variant p.Gly54Asp in the 
patients. In this regard, another study highlighted that the relationship between MBL deficiency and 
disease is complex and depends on different genetic and environmental factors, and that could explain 
why the data obtained in different studies are sometimes contradictory.
33
 The present study correlates the 
genotype p.Gly54Asp with MBL deficiency and indicates a protective effect from AMR, where the 
complement pathway plays a key role. However, we did not found significant association between this 
polymorphism and CAV. 
Increased risk of AMR in patients with p.Asn428(p=) in CFP gene 
The p.Asn428(p=) in CFP gene (rs1048118) is the second SNP significantly and positively associated 
with AMR. This variant in patients with AMR correlates with higher concentration of properdin than in 
control patients. The CFP gene encodes the properdin protein, also known as factor P. Properdin 
stabilizes the active enzyme complex of the alternative pathway and is the only known positive regulator 
of complement activation.
34,35
 It has been shown that properdin deficiency results in an increased risk of 
infection; infection mortality rates of 33%–75% have been reported.36 It has been hypothesized that 
higher levels of properdin, such as the levels shown in our AMR cohort, result in a higher capacity to 
activate the alternative pathway and may therefore represent activation of the alternative pathway in 
relevant situations, such as cardiovascular events,
37
 type 2 diabetes mellitus,
38
 and AMR. Human studies 
on the alternative pathway factor properdin in relation to transplantation are scarce. The most relevant 
article in this area focused on cellular rejection.
39
 The authors showed that ISHLT grade 3A heart biopsy 
specimens (moderate rejection or 2R) contained significantly more transcripts than grade 0 or 1 biopsy 
specimens for properdin. Taking all these data together, we can hypothesize that high levels of properdin, 
owing to the presence of the rs1048118 SNP, could have an important role in the development of AMR or 
cellular rejection. 
Limitations of the study 
Limitations of this study include its retrospective single-center design, different criteria of AMR 
definition, and clinical differences between groups. Moreover, because of the relatively small sample size, 
we were unable to perform multivariate analysis. 
Conclusions 
AMR in HT is a complex entity. We have described variants of genes related to the complement 
system associated with this phenotype. Specifically, the variants CFP (p.Asn428 (p=)) and MBL2 
(p.Gly54Asp) are associated with an increase and a reduction of the associated risk of AMR, respectively. 
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